HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valentino license

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble Prestige Beauté, the beauty division's fine fragrance unit, signed a licensing agreement with Italian fashion designer Valentino to market fragrance and beauty products under the designer name effective Aug. 1, company announces July 30. Valentino license has global growth potential, P&G says, noting agreement is in line with corporate strategy to "develop faster-growing, higher margin, more asset efficient businesses with global leadership potential." Valentino brand has feminine, glamorous heritage that will complement P&G's existing fine fragrance portfolio, firm says. Lineup, which currently includes Hugo Boss, Jean Patou and Lacoste, also will be expanded with addition of Wella fragrance brands. Valentino fragrances previously were marketed by Unilever Prestige...

You may also be interested in...

P&G/Clarins deal

Clarins Fragrance Group will distribute fragrances under the Valentino label in the U.S. under deal with Procter & Gamble, effective immediately, firms announce. Clarins, which distributes P&G's Jean Patou and Lacoste fragrances in specialty stores, department stores and boutiques, maintains it is well suited to distribute the specialty-door Valentino brand. P&G's Prestige Beaute division recently signed a licensing agreement with the Italian designer Valentino to market the brand's fragrances and beauty products (1"The Rose Sheet" Aug. 4, 2003, In Brief)...

Novo Executive Calls For ‘Real AMR Action’ In Davos

The Novo Nordisk Foundation is sponsoring a panel at Davos this week on finding solutions to the global crisis on antimicrobial resistance – and hopes world leaders will listen.

Roche Gears Up For Potential Neuroscience Breakthroughs

Neuroscience could be this decade’s big growth story, but clinical and market access challenges differ to oncology.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts